Analysts predict that Mednax, Inc (NYSE:MD) will post sales of $886.36 million for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for Mednax’s earnings. The highest sales estimate is $894.51 million and the lowest is $876.50 million. Mednax reported sales of $830.77 million in the same quarter last year, which would suggest a positive year over year growth rate of 6.7%. The firm is expected to issue its next earnings report on Tuesday, February 6th.

On average, analysts expect that Mednax will report full-year sales of $886.36 million for the current financial year, with estimates ranging from $3.42 billion to $3.44 billion. For the next year, analysts expect that the firm will report sales of $3.66 billion per share, with estimates ranging from $3.59 billion to $3.75 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Mednax.

Mednax (NYSE:MD) last announced its earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.87. The business had revenue of $868.95 million during the quarter, compared to analyst estimates of $864.78 million. Mednax had a return on equity of 10.80% and a net margin of 7.76%. Mednax’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period last year, the company earned $1.09 EPS.

Several research analysts recently issued reports on MD shares. BidaskClub lowered Mednax from a “sell” rating to a “strong sell” rating in a research report on Friday, August 4th. Robert W. Baird reiterated a “hold” rating and set a $47.00 price target on shares of Mednax in a report on Sunday, September 3rd. Zacks Investment Research upgraded Mednax from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. KeyCorp set a $51.00 price target on Mednax and gave the stock a “buy” rating in a report on Wednesday, November 1st. Finally, BMO Capital Markets initiated coverage on Mednax in a report on Monday, October 16th. They set a “market perform” rating and a $46.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $54.50.

Shares of Mednax (MD) traded down $0.39 during trading hours on Friday, reaching $49.79. The company had a trading volume of 6,400,200 shares, compared to its average volume of 1,082,931. The company has a market cap of $4,610.00, a price-to-earnings ratio of 15.05, a P/E/G ratio of 1.59 and a beta of 0.32. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.37 and a current ratio of 1.37. Mednax has a twelve month low of $40.56 and a twelve month high of $72.13.

In other news, Director Cesar L. Alvarez sold 10,668 shares of the firm’s stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $42.59, for a total value of $454,350.12. Following the completion of the sale, the director now directly owns 44,215 shares in the company, valued at approximately $1,883,116.85. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total value of $128,550.00. Following the completion of the sale, the insider now owns 35,569 shares of the company’s stock, valued at $1,524,131.65. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Fuller & Thaler Asset Management Inc. acquired a new position in Mednax during the 3rd quarter valued at about $103,000. Pacer Advisors Inc. boosted its stake in Mednax by 8.1% during the 2nd quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock valued at $117,000 after purchasing an additional 145 shares during the last quarter. Commonwealth Bank of Australia boosted its stake in Mednax by 15.3% during the 2nd quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock valued at $132,000 after purchasing an additional 293 shares during the last quarter. Daiwa Securities Group Inc. boosted its stake in Mednax by 20.0% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,000 shares of the company’s stock valued at $181,000 after purchasing an additional 500 shares during the last quarter. Finally, Denali Advisors LLC acquired a new position in Mednax during the 3rd quarter valued at about $185,000. Institutional investors own 98.44% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Mednax, Inc (MD) Expected to Post Quarterly Sales of $886.36 Million” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/01/mednax-inc-md-expected-to-post-quarterly-sales-of-886-36-million.html.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Get a free copy of the Zacks research report on Mednax (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.